Department of Medicine

New trial results from the University of Vermont and an international team of researchers show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could reduce the risk of severe disease and death.

Investigators from across the globe came together virtually July 12-15, 2021 for the University of Vermont-hosted ninth biennial "Stem Cells, Cell Therapies, and Bioengineering in Lung Biology" conference to share the latest research in the field and set priorities for their work in the future.